# FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma

> fda · REPORTED · 2026-07-28

The FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) combined with nivolumab for patients with anti-PD-1 therapy-pretreated advanced melanoma, adding a new option for this difficult-to-treat patient population. The approval covers patients whose disease has progressed on prior checkpoint inhibitor therapy.

About Replimune: Replimune develops oncolytic virus-based immunotherapies, with RP1 (vusolimogene oderparepvec) designed to selectively infect and kill tumor cells while stimulating a systemic anti-tumor immune response, targeting advanced solid tumors.

- Company: Replimune
- Sector: oncology
- Primary source: https://www.onclive.com/clinical/news

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.